Liminatus Pharma entered into engagement agreement with Digital Offering

Liminatus Pharma (LIMN) announced it has entered into an engagement agreement with Digital Offering to serve as its exclusive placement agent in connection with the company’s evaluation of a potential strategic capital raise. This engagement supports Liminatus’s previously disclosed review of a digital asset treasury strategy, as the company evaluates modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt financing structures, including-but not limited to-convertible debentures, equity-linked securities, or other alternative instruments that comply with applicable U.S. securities laws. Under this engagement agreement, Digital Offering is engaged to assist the company in sourcing institutional and digital asset-focused investors and structuring a compliant financing solution.